AI-Powered Revenue Cycle Platform Will Benefit From Expanding Healthcare Data And Network Effects

Catalysts

About Waystar Holding

Waystar Holding provides AI driven software that helps health care providers manage the full revenue cycle and get paid accurately and efficiently.

What are the underlying business or industry changes driving this perspective?

• Growing reliance on AI driven revenue cycle tools across health care, with roughly 50% of Waystar solutions using AI and about 40% of revenue tied to AI embedded workflows, supports potential expansion of high value software revenue and earnings quality.
• Rising complexity in payer rules and denials, combined with AltitudeAI’s track record of preventing more than US$15b in denials and shortening appeal cycles, points to further scope for automation gains that may support revenue growth and healthier net margins.
• Expansion of the integrated financial and clinical platform after the Iodine acquisition, covering about one third of U.S. hospital discharges, increases cross sell potential across more than 1,000 largely non overlapping hospital customers, which can support subscription revenue and EBITDA growth.
• Waystar’s position in the payment flow, processing over 7b transactions annually and touching about 60% of the U.S. patient population, creates a reinforcing data and network effect that can help sustain high client retention, support recurring revenue and stabilize earnings.
• Record bookings in Q4 2025, a growing base of clients spending more than US$100,000 annually and a large implementation backlog all point to multi quarter visibility on new deployments, which can feed into future revenue, EBITDA and free cash flow.

Assumptions

This narrative explores a more optimistic perspective on Waystar Holding compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Waystar Holding's revenue will grow by 13.7% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 10.2% today to 26.7% in 3 years time.
• The bullish analysts expect earnings to reach $431.0 million (and earnings per share of $2.18) by about February 2029, up from $112.1 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $229.8 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 38.1x on those 2029 earnings, down from 41.6x today. This future PE is lower than the current PE for the US Healthcare Services industry at 41.6x.
• The bullish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Health care providers may slow or scale back AI adoption if internal priorities, regulatory concerns or budget constraints shift. This could temper demand for new AI agents and limit the share of revenue tied to AI-embedded workflows, affecting revenue and earnings.
• New AI-focused entrants, large technology platforms and electronic health record vendors are all trying to push their own tools into revenue cycle management. If hospitals choose a patchwork of point solutions or in-house projects instead of a unified platform, Waystar’s win rates and cross-sell potential could come under pressure, impacting revenue and EBITDA.
• The company’s model depends heavily on transaction volumes and patient utilization of health care. Any long-term moderation in visit trends or a shift in payer practices that reduces claim volumes or patient payment activity could weigh on volume-based revenue and compress net margins.
• Waystar is investing to integrate Iodine and to launch multiple new AI agents. If integration synergies or new product monetization are slower or smaller than planned while spending remains elevated, adjusted EBITDA margins and free cash flow conversion could come under strain.
• The business holds extensive financial and clinical data and operates at the center of payer, provider and patient flows. Any cyber incident, regulatory change around data use or tightening compliance standards could raise operating costs, constrain how data feeds AI models and potentially pressure margins and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Waystar Holding is $54.0, which represents up to two standard deviations above the consensus price target of $43.5. This valuation is based on what can be assumed as the expectations of Waystar Holding's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $54.0, and the most bearish reporting a price target of just $30.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $1.6 billion, earnings will come to $431.0 million, and it would be trading on a PE ratio of 38.1x, assuming you use a discount rate of 9.0%.
  
• Given the current share price of $24.31, the analyst price target of $54.0 is 55.0% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.